Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis.

Smeester BA, Slipek NJ, Pomeroy EJ, Bomberger HE, Shamsan GA, Peterson JJ, Crosby MR, Draper GM, Becklin KL, Rahrmann EP, McCarthy JB, Odde DJ, Wood DK, Largaespada DA, Moriarity BS.

Oncogene. 2019 Oct 3. doi: 10.1038/s41388-019-1041-x. [Epub ahead of print]

PMID:
31582836
2.

Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis.

Huang M, Tailor J, Zhen Q, Gillmor AH, Miller ML, Weishaupt H, Chen J, Zheng T, Nash EK, McHenry LK, An Z, Ye F, Takashima Y, Clarke J, Ayetey H, Cavalli FMG, Luu B, Moriarity BS, Ilkhanizadeh S, Chavez L, Yu C, Kurian KM, Magnaldo T, Sevenet N, Koch P, Pollard SM, Dirks P, Snyder MP, Largaespada DA, Cho YJ, Phillips JJ, Swartling FJ, Morrissy AS, Kool M, Pfister SM, Taylor MD, Smith A, Weiss WA.

Cell Stem Cell. 2019 Sep 5;25(3):433-446.e7. doi: 10.1016/j.stem.2019.05.013. Epub 2019 Jun 13.

3.

A comparison of risk factors for metastasis at diagnosis in humans and dogs with osteosarcoma.

Diessner BJ, Marko TA, Scott RM, Eckert AL, Stuebner KM, Hohenhaus AE, Selting KA, Largaespada DA, Modiano JF, Spector LG.

Cancer Med. 2019 Jun;8(6):3216-3226. doi: 10.1002/cam4.2177. Epub 2019 Apr 21.

4.

HBx-K130M/V131I Promotes Liver Cancer in Transgenic Mice via AKT/FOXO1 Signaling Pathway and Arachidonic Acid Metabolism.

Chiu AP, Tschida BR, Sham TT, Lo LH, Moriarity BS, Li XX, Lo RC, Hinton DE, Rowlands DK, Chan CO, Mok DKW, Largaespada DA, Warner N, Keng VW.

Mol Cancer Res. 2019 Jul;17(7):1582-1593. doi: 10.1158/1541-7786.MCR-18-1127. Epub 2019 Apr 11.

PMID:
30975706
5.

Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.

Ramkissoon A, Chaney KE, Milewski D, Williams KB, Williams RL, Choi K, Miller A, Kalin TV, Pressey JG, Szabo S, Azam M, Largaespada DA, Ratner N.

Clin Cancer Res. 2019 Jul 1;25(13):4117-4127. doi: 10.1158/1078-0432.CCR-18-3224. Epub 2019 Apr 1.

PMID:
30936125
6.

Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas.

Rathe SK, Popescu FE, Johnson JE, Watson AL, Marko TA, Moriarity BS, Ohlfest JR, Largaespada DA.

Sci Rep. 2019 Jan 23;9(1):358. doi: 10.1038/s41598-018-36840-z.

7.

Sleeping Beauty Insertional Mutagenesis Reveals Important Genetic Drivers of Central Nervous System Embryonal Tumors.

Beckmann PJ, Larson JD, Larsson AT, Ostergaard JP, Wagner S, Rahrmann EP, Shamsan GA, Otto GM, Williams RL, Wang J, Lee C, Tschida BR, Das P, Dubuc AM, Moriarity BS, Picard D, Wu X, Rodriguez FJ, Rosemarie Q, Krebs RD, Molan AM, Demer AM, Frees MM, Rizzardi AE, Schmechel SC, Eberhart CG, Jenkins RB, Wechsler-Reya RJ, Odde DJ, Huang A, Taylor MD, Sarver AL, Largaespada DA.

Cancer Res. 2019 Mar 1;79(5):905-917. doi: 10.1158/0008-5472.CAN-18-1261. Epub 2019 Jan 23.

PMID:
30674530
8.

Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation.

Li XX, Lu XY, Zhang SJ, Chiu AP, Lo LH, Largaespada DA, Chen QB, Keng VW.

Biomed Pharmacother. 2019 Mar;111:68-75. doi: 10.1016/j.biopha.2018.12.019. Epub 2018 Dec 18.

9.

CRISPR/Cas9-Based Positive Screens for Cancer-Related Traits.

Slipek NJ, Varshney J, Largaespada DA.

Methods Mol Biol. 2019;1907:137-144. doi: 10.1007/978-1-4939-8967-6_11.

PMID:
30542997
10.

Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis.

Fan Y, Bazai SK, Daian F, Arechederra M, Richelme S, Temiz NA, Yim A, Habermann BH, Dono R, Largaespada DA, Maina F.

J Hepatol. 2019 Mar;70(3):470-482. doi: 10.1016/j.jhep.2018.11.027. Epub 2018 Dec 6.

PMID:
30529386
11.

Sleeping Beauty Screen Identifies RREB1 and Other Genetic Drivers in Human B-cell Lymphoma.

Rahrmann EP, Wolf NK, Otto GM, Heltemes-Harris L, Ramsey LB, Shu J, LaRue RS, Linden MA, Rathe SK, Starr TK, Farrar MA, Moriarity BS, Largaespada DA.

Mol Cancer Res. 2019 Feb;17(2):567-582. doi: 10.1158/1541-7786.MCR-18-0582. Epub 2018 Oct 24.

PMID:
30355676
12.

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1.

Isakson SH, Rizzardi AE, Coutts AW, Carlson DF, Kirstein MN, Fisher J, Vitte J, Williams KB, Pluhar GE, Dahiya S, Widemann BC, Dombi E, Rizvi T, Ratner N, Messiaen L, Stemmer-Rachamimov AO, Fahrenkrug SC, Gutmann DH, Giovannini M, Moertel CL, Largaespada DA, Watson AL.

Commun Biol. 2018 Oct 2;1:158. doi: 10.1038/s42003-018-0163-y. eCollection 2018.

13.

Social stress shortens lifespan in mice.

Razzoli M, Nyuyki-Dufe K, Gurney A, Erickson C, McCallum J, Spielman N, Marzullo M, Patricelli J, Kurata M, Pope EA, Touma C, Palme R, Largaespada DA, Allison DB, Bartolomucci A.

Aging Cell. 2018 Aug;17(4):e12778. doi: 10.1111/acel.12778. Epub 2018 May 28.

14.

Transcriptomic analysis of gene signatures associated with sickle pain.

Paul JA, Aich A, Abrahante JE, Wang Y, LaRue RS, Rathe SK, Kalland K, Mittal A, Jha R, Peng F, Largaespada DA, Bagchi A, Gupta K.

Sci Data. 2017 May 16;4:170051. doi: 10.1038/sdata.2017.51.

15.

Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors.

Carlson M, Watson AL, Anderson L, Largaespada DA, Provenzano PP.

J Biomed Opt. 2017 Nov;22(11):1-9. doi: 10.1117/1.JBO.22.11.116010.

16.

CRISPR/Cas9 library screening for drug target discovery.

Kurata M, Yamamoto K, Moriarity BS, Kitagawa M, Largaespada DA.

J Hum Genet. 2018 Feb;63(2):179-186. doi: 10.1038/s10038-017-0376-9. Epub 2017 Nov 20. Review.

PMID:
29158600
17.

Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma.

Scott MC, Temiz NA, Sarver AE, LaRue RS, Rathe SK, Varshney J, Wolf NK, Moriarity BS, O'Brien TD, Spector LG, Largaespada DA, Modiano JF, Subramanian S, Sarver AL.

Cancer Res. 2018 Jan 15;78(2):326-337. doi: 10.1158/0008-5472.CAN-17-0576. Epub 2017 Oct 24.

18.

Sleeping Beauty Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors.

Tschida BR, Temiz NA, Kuka TP, Lee LA, Riordan JD, Tierrablanca CA, Hullsiek R, Wagner S, Hudson WA, Linden MA, Amin K, Beckmann PJ, Heuer RA, Sarver AL, Yang JD, Roberts LR, Nadeau JH, Dupuy AJ, Keng VW, Largaespada DA.

Cancer Res. 2017 Dec 1;77(23):6576-6588. doi: 10.1158/0008-5472.CAN-17-2281. Epub 2017 Oct 9.

19.

Chronic liver injury alters driver mutation profiles in hepatocellular carcinoma in mice.

Riordan JD, Feddersen CR, Tschida BR, Beckmann PJ, Keng VW, Linden MA, Amin K, Stipp CS, Largaespada DA, Dupuy AJ.

Hepatology. 2018 Mar;67(3):924-939. doi: 10.1002/hep.29565. Epub 2018 Jan 26.

20.

Transposons As Tools for Functional Genomics in Vertebrate Models.

Kawakami K, Largaespada DA, Ivics Z.

Trends Genet. 2017 Nov;33(11):784-801. doi: 10.1016/j.tig.2017.07.006. Epub 2017 Sep 6. Review.

21.

CFTR is a tumor suppressor gene in murine and human intestinal cancer.

Than BLN, Linnekamp JF, Starr TK, Largaespada DA, Rod A, Zhang Y, Bruner V, Abrahante J, Schumann A, Luczak T, Walter J, Niemczyk A, O'Sullivan MG, Medema JP, Fijneman RJA, Meijer GA, Van den Broek E, Hodges CA, Scott PM, Vermeulen L, Cormier RT.

Oncogene. 2017 Jun 15;36(24):3504. doi: 10.1038/onc.2017.3. Epub 2017 Feb 13.

PMID:
28192405
22.

Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.

Pomeroy EJ, Lee LA, Lee RDW, Schirm DK, Temiz NA, Ma J, Gruber TA, Diaz-Flores E, Moriarity BS, Downing JR, Shannon KM, Largaespada DA, Eckfeldt CE.

Oncogene. 2017 Jun 8;36(23):3263-3273. doi: 10.1038/onc.2016.471. Epub 2016 Dec 19.

23.

Slit-Robo GTPase-Activating Protein 2 as a metastasis suppressor in osteosarcoma.

Marko TA, Shamsan GA, Edwards EN, Hazelton PE, Rathe SK, Cornax I, Overn PR, Varshney J, Diessner BJ, Moriarity BS, O'Sullivan MG, Odde DJ, Largaespada DA.

Sci Rep. 2016 Dec 14;6:39059. doi: 10.1038/srep39059.

24.

Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML.

Kurata M, Rathe SK, Bailey NJ, Aumann NK, Jones JM, Veldhuijzen GW, Moriarity BS, Largaespada DA.

Sci Rep. 2016 Nov 3;6:36199. doi: 10.1038/srep36199.

25.

RALB provides critical survival signals downstream of Ras in acute myeloid leukemia.

Eckfeldt CE, Pomeroy EJ, Lee RD, Hazen KS, Lee LA, Moriarity BS, Largaespada DA.

Oncotarget. 2016 Oct 4;7(40):65147-65156. doi: 10.18632/oncotarget.11431.

26.

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.

Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ.

J Clin Invest. 2016 Sep 1;126(9):3363-76. doi: 10.1172/JCI86721. Epub 2016 Aug 2.

27.

CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin.

Kendall JJ, Chaney KE, Patel AV, Rizvi TA, Largaespada DA, Ratner N.

Oncotarget. 2016 Aug 16;7(33):53191-53203. doi: 10.18632/oncotarget.10668.

28.

Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.

Sachs Z, Been RA, DeCoursin KJ, Nguyen HT, Mohd Hassan NA, Noble-Orcutt KE, Eckfeldt CE, Pomeroy EJ, Diaz-Flores E, Geurts JL, Diers MD, Hasz DE, Morgan KJ, MacMillan ML, Shannon KM, Largaespada DA, Wiesner SM.

Haematologica. 2016 Oct;101(10):1190-1199. Epub 2016 Jul 14.

29.

An ShRNA Screen Identifies MEIS1 as a Driver of Malignant Peripheral Nerve Sheath Tumors.

Patel AV, Chaney KE, Choi K, Largaespada DA, Kumar AR, Ratner N.

EBioMedicine. 2016 Jul;9:110-119. doi: 10.1016/j.ebiom.2016.06.007. Epub 2016 Jun 4.

30.

Engineered Swine Models of Cancer.

Watson AL, Carlson DF, Largaespada DA, Hackett PB, Fahrenkrug SC.

Front Genet. 2016 May 9;7:78. doi: 10.3389/fgene.2016.00078. eCollection 2016. Review.

31.

Case-oriented pathways analysis in pancreatic adenocarcinoma using data from a sleeping beauty transposon mutagenesis screen.

Ho YY, Starr TK, LaRue RS, Largaespada DA.

BMC Med Genomics. 2016 Apr 1;9:16. doi: 10.1186/s12920-016-0176-7.

32.

Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasms.

Stoddart A, Qian Z, Fernald AA, Bergerson RJ, Wang J, Karrison T, Anastasi J, Bartom ET, Sarver AL, McNerney ME, Largaespada DA, Le Beau MM.

Haematologica. 2016 Jun;101(6):e232-6. doi: 10.3324/haematol.2015.139527. Epub 2016 Mar 4. No abstract available.

33.

Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.

Wu J, Keng VW, Patmore DM, Kendall JJ, Patel AV, Jousma E, Jessen WJ, Choi K, Tschida BR, Silverstein KA, Fan D, Schwartz EB, Fuchs JR, Zou Y, Kim MO, Dombi E, Levy DE, Huang G, Cancelas JA, Stemmer-Rachamimov AO, Spinner RJ, Largaespada DA, Ratner N.

Cell Rep. 2016 Mar 1;14(8):1979-90. doi: 10.1016/j.celrep.2016.01.074. Epub 2016 Feb 18.

34.

Imprinting defects at human 14q32 locus alters gene expression and is associated with the pathobiology of osteosarcoma.

Shu J, Li L, Sarver AE, Pope EA, Varshney J, Thayanithy V, Spector L, Largaespada DA, Steer CJ, Subramanian S.

Oncotarget. 2016 Apr 19;7(16):21298-314. doi: 10.18632/oncotarget.6965.

35.

Understanding the Osteosarcoma Pathobiology: A Comparative Oncology Approach.

Varshney J, Scott MC, Largaespada DA, Subramanian S.

Vet Sci. 2016 Jan 18;3(1). pii: E3. doi: 10.3390/vetsci3010003. Review.

36.

Divergent clonal selection dominates medulloblastoma at recurrence.

Morrissy AS, Garzia L, Shih DJ, Zuyderduyn S, Huang X, Skowron P, Remke M, Cavalli FM, Ramaswamy V, Lindsay PE, Jelveh S, Donovan LK, Wang X, Luu B, Zayne K, Li Y, Mayoh C, Thiessen N, Mercier E, Mungall KL, Ma Y, Tse K, Zeng T, Shumansky K, Roth AJ, Shah S, Farooq H, Kijima N, Holgado BL, Lee JJ, Matan-Lithwick S, Liu J, Mack SC, Manno A, Michealraj KA, Nor C, Peacock J, Qin L, Reimand J, Rolider A, Thompson YY, Wu X, Pugh T, Ally A, Bilenky M, Butterfield YS, Carlsen R, Cheng Y, Chuah E, Corbett RD, Dhalla N, He A, Lee D, Li HI, Long W, Mayo M, Plettner P, Qian JQ, Schein JE, Tam A, Wong T, Birol I, Zhao Y, Faria CC, Pimentel J, Nunes S, Shalaby T, Grotzer M, Pollack IF, Hamilton RL, Li XN, Bendel AE, Fults DW, Walter AW, Kumabe T, Tominaga T, Collins VP, Cho YJ, Hoffman C, Lyden D, Wisoff JH, Garvin JH Jr, Stearns DS, Massimi L, Schüller U, Sterba J, Zitterbart K, Puget S, Ayrault O, Dunn SE, Tirapelli DP, Carlotti CG, Wheeler H, Hallahan AR, Ingram W, MacDonald TJ, Olson JJ, Van Meir EG, Lee JY, Wang KC, Kim SK, Cho BK, Pietsch T, Fleischhack G, Tippelt S, Ra YS, Bailey S, Lindsey JC, Clifford SC, Eberhart CG, Cooper MK, Packer RJ, Massimino M, Garre ML, Bartels U, Tabori U, Hawkins CE, Dirks P, Bouffet E, Rutka JT, Wechsler-Reya RJ, Weiss WA, Collier LS, Dupuy AJ, Korshunov A, Jones DT, Kool M, Northcott PA, Pfister SM, Largaespada DA, Mungall AJ, Moore RA, Jabado N, Bader GD, Jones SJ, Malkin D, Marra MA, Taylor MD.

Nature. 2016 Jan 21;529(7586):351-7. doi: 10.1038/nature16478. Epub 2016 Jan 13.

37.

CFTR is a tumor suppressor gene in murine and human intestinal cancer.

Than BL, Linnekamp JF, Starr TK, Largaespada DA, Rod A, Zhang Y, Bruner V, Abrahante J, Schumann A, Luczak T, Walter J, Niemczyk A, O'Sullivan MG, Medema JP, Fijneman RJ, Meijer GA, Van den Broek E, Hodges CA, Scott PM, Vermeulen L, Cormier RT.

Oncogene. 2016 Aug 11;35(32):4179-87. doi: 10.1038/onc.2015.483. Epub 2016 Jan 11. Erratum in: Oncogene. 2017 Jun 15;36(24):3504.

38.

Coping with cancer genes altered by copy number.

Wolf NK, Largaespada DA, Moriarity BS.

Oncotarget. 2015 Nov 3;6(34):35155-6. doi: 10.18632/oncotarget.6215. No abstract available.

39.

Transposon mouse models to elucidate the genetic mechanisms of hepatitis B viral induced hepatocellular carcinoma.

Chiu AP, Tschida BR, Lo LH, Moriarity BS, Rowlands DK, Largaespada DA, Keng VW.

World J Gastroenterol. 2015 Nov 14;21(42):12157-70. doi: 10.3748/wjg.v21.i42.12157. Review.

40.

RNA sequencing of Sleeping Beauty transposon-induced tumors detects transposon-RNA fusions in forward genetic cancer screens.

Temiz NA, Moriarity BS, Wolf NK, Riordan JD, Dupuy AJ, Largaespada DA, Sarver AL.

Genome Res. 2016 Jan;26(1):119-29. doi: 10.1101/gr.188649.114. Epub 2015 Nov 9.

41.

Sleeping Beauty transposon screen identifies signaling modules that cooperate with STAT5 activation to induce B-cell acute lymphoblastic leukemia.

Heltemes-Harris LM, Larson JD, Starr TK, Hubbard GK, Sarver AL, Largaespada DA, Farrar MA.

Oncogene. 2016 Jun 30;35(26):3454-64. doi: 10.1038/onc.2015.405. Epub 2015 Oct 26.

42.

Synthesis and antileukemic activities of C1-C10-modified parthenolide analogues.

Kempema AM, Widen JC, Hexum JK, Andrews TE, Wang D, Rathe SK, Meece FA, Noble KE, Sachs Z, Largaespada DA, Harki DA.

Bioorg Med Chem. 2015 Aug 1;23(15):4737-45. doi: 10.1016/j.bmc.2015.05.037. Epub 2015 May 30.

43.

Sleeping Beauty transposon insertional mutagenesis based mouse models for cancer gene discovery.

Moriarity BS, Largaespada DA.

Curr Opin Genet Dev. 2015 Feb;30:66-72. doi: 10.1016/j.gde.2015.04.007. Epub 2015 Jun 4. Review.

44.

Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor.

Dorr C, Janik C, Weg M, Been RA, Bader J, Kang R, Ng B, Foran L, Landman SR, O'Sullivan MG, Steinbach M, Sarver AL, Silverstein KA, Largaespada DA, Starr TK.

Mol Cancer Res. 2015 Aug;13(8):1238-47. doi: 10.1158/1541-7786.MCR-14-0674-T. Epub 2015 May 20.

45.

Parthenolide prodrug LC-1 slows growth of intracranial glioma.

Hexum JK, Becker CM, Kempema AM, Ohlfest JR, Largaespada DA, Harki DA.

Bioorg Med Chem Lett. 2015 Jun 15;25(12):2493-5. doi: 10.1016/j.bmcl.2015.04.058. Epub 2015 Apr 25.

PMID:
25978958
46.

Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.

Becker CM, Oberoi RK, McFarren SJ, Muldoon DM, Pafundi DH, Pokorny JL, Brinkmann DH, Ohlfest JR, Sarkaria JN, Largaespada DA, Elmquist WF.

Neuro Oncol. 2015 Sep;17(9):1210-9. doi: 10.1093/neuonc/nov081. Epub 2015 May 12.

47.

A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis.

Moriarity BS, Otto GM, Rahrmann EP, Rathe SK, Wolf NK, Weg MT, Manlove LA, LaRue RS, Temiz NA, Molyneux SD, Choi K, Holly KJ, Sarver AL, Scott MC, Forster CL, Modiano JF, Khanna C, Hewitt SM, Khokha R, Yang Y, Gorlick R, Dyer MA, Largaespada DA.

Nat Genet. 2015 Jun;47(6):615-24. doi: 10.1038/ng.3293. Epub 2015 May 11.

48.

NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.

Sachs Z, LaRue RS, Nguyen HT, Sachs K, Noble KE, Mohd Hassan NA, Diaz-Flores E, Rathe SK, Sarver AL, Bendall SC, Ha NA, Diers MD, Nolan GP, Shannon KM, Largaespada DA.

Blood. 2014 Nov 20;124(22):3274-83. doi: 10.1182/blood-2013-08-521708. Epub 2014 Oct 14.

49.

Using RNA-seq and targeted nucleases to identify mechanisms of drug resistance in acute myeloid leukemia.

Rathe SK, Moriarity BS, Stoltenberg CB, Kurata M, Aumann NK, Rahrmann EP, Bailey NJ, Melrose EG, Beckmann DA, Liska CR, Largaespada DA.

Sci Rep. 2014 Aug 13;4:6048. doi: 10.1038/srep06048.

50.

PVT1 dependence in cancer with MYC copy-number increase.

Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, Ronning P, Reuland B, Guenther K, Beadnell TC, Essig J, Otto GM, O'Sullivan MG, Largaespada DA, Schwertfeger KL, Marahrens Y, Kawakami Y, Bagchi A.

Nature. 2014 Aug 7;512(7512):82-6. doi: 10.1038/nature13311. Epub 2014 Jun 22.

Supplemental Content

Loading ...
Support Center